Go Deep
Core Laboratories Inc.
Core Laboratories Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 22,096 | 19.5 | 1.71 | 0.59 | 967.57 |
| Oct 2026 | 22,225 | 18.8 | 1.64 | 0.59 | 927.64 |
| Oct 2026 | 22,221 | 19.6 | 1.65 | 0.59 | 928.72 |
| Oct 2026 | 22,149 | 19.2 | 1.68 | 0.59 | 947.15 |
| Oct 2026 | 21,699 | 19.5 | 1.71 | 0.59 | 962.39 |
| Oct 2026 | 21,729 | 19.3 | 1.69 | 0.59 | 953.85 |
| Oct 2026 | 21,705 | 19.5 | 1.71 | 0.59 | 958.12 |
| Oct 2026 | 21,948 | 18.1 | 1.58 | 0.59 | 887.27 |
Core Laboratories Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 124,609,000.0 | 121,797,000.0 | 138,255,000.0 | 134,521,000.0 |
| Net Profit | 5,956,000.0 | -789,000.0 | 4,948,000.0 | 14,239,000.0 |
| EPS | 0.1 | -0.0 | 0.2 | 0.3 |
Core Laboratories Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 526,520,000.0 | 523,848,000.0 | 509,790,000.0 | 489,735,000.0 | — |
| Net Profit | 29,669,000.0 | 31,400,000.0 | 36,675,000.0 | 19,453,000.0 | — |
| EPS | 0.6 | 0.7 | 0.9 | 0.4 | — |
Core Laboratories Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 584,010,000.0 | 585,130,000.0 | 586,395,000.0 | 578,354,000.0 | — |
| Total Liabilities | 311,802,000.0 | 332,812,000.0 | 356,588,000.0 | 389,400,000.0 | — |
| Total Equity | 265,986,000.0 | 246,573,000.0 | 224,815,000.0 | 184,258,000.0 | — |
Owes vs Owns
Core Laboratories Inc. owed $0.52 for every $1 it owned in Jun 2026, down from $0.67 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.52× | 0.53× | 0.57× | 0.61× | 0.67× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Core Laboratories Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 3.9%Receivables 20.7%Inventory 9.3%Fixed assets (tangible) 26.3%Intangible assets 19.3%Long-term investments 0.8%Other assets 19.7%
How it's funded — Dec 2025
Short-term debt 2.0%Long-term debt 18.9%Payables 6.4%Other liabilities 26.2%Shareholders' equity 46.6%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 22.7 | 19.2 | 15.1 | 15.4 |
| Receivables | 120.8 | 122.1 | 123.1 | 115.1 |
| Inventory | 54.5 | 59.4 | 71.7 | 60.4 |
| Fixed assets (tangible) | 153.8 | 153.6 | 153.5 | 157.4 |
| Intangible assets | 112.9 | 105.8 | 106.4 | 106.9 |
| Long-term investments | 4.4 | 5.1 | 4.8 | 4.5 |
| Other assets | 114.9 | 120.0 | 111.8 | 118.6 |
| Liabilities & equity | ||||
| Short-term debt | 11.5 | 10.7 | 10.2 | 11.7 |
| Long-term debt | 110.3 | 126.1 | 163.1 | 172.4 |
| Payables | 37.3 | 34.5 | 33.5 | 45.8 |
| Other liabilities | 152.8 | 161.5 | 149.8 | 159.5 |
| Shareholders' equity | 272.2 | 252.3 | 229.8 | 189.0 |
| Net tangible assets | 153.1 | 140.7 | 118.4 | 77.3 |
Core Laboratories Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 37,031,000.0 | 56,388,000.0 | 24,789,000.0 | 24,956,000.0 | — |
| Investing Activities | -2,231,000.0 | -6,394,000.0 | -6,652,000.0 | -3,856,000.0 | — |
| Financing Activities | -31,255,000.0 | -45,957,000.0 | -18,445,000.0 | -23,375,000.0 | — |